Essential hypertension
Conditions
Interventions
Negative control group:Qingda particle simulator
Experimental group:Qingda granules
Sponsors
Long Linzi
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients met the diagnostic criteria of hypertension level 1 according to the unified office blood pressure measurement, and the risk stratification was low and intermediate risk (according to the Chinese Guidelines for the prevention and treatment of Hypertension, revised edition 2018) Not taking antihypertensive drugs within one month TCM syndrome differentiation conforms to the liver-Yang hyperthyroidism syndrome Age between 20 and 75 years old (including boundary values) Sign the informed consent form
Exclusion criteria
Exclusion criteria: Patients with obvious liver and kidney diseases or glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase are 1.5 times higher than normal value, and creatinine and urea nitrogen are 2 times higher than normal value Have the following diseases: Acute myocardial infarction, cerebrovascular accident, transient ischemic attack, large aneurysm or dissecting aneurysm, unstable angina pectoris, heart failure history of Grade II-IV (NYHA scale), atrioventricular block of grade II and above, sick sinus syndrome, bradycardia (heart rate < < 50 times/min) or patients with malignant or potentially malignant arrhythmias such as atrial fibrillation, serious mental diseases, diseases of the hematopoietic system, malignant tumors and other major diseases Secondary hypertension, including but not limited to the following diseases: unilateral or double renal arteries, polycystic kidney disease, hyperaldosteronism, coarctation of the aorta, Cushing's syndrome, pheochromocytoma Circadian rhythm reversal or irregular sleep pattern pregnancy, lactation or family planning within 6 months Have participated in or are participating in other clinical investigators within the last three months Suspected or clear allergy to the study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in office systolic blood pressure after 4 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ambulatory blood pressure control after 4 weeks of treatment;Vasoactive substances after 4 weeks of treatment;Changes of total score of liver-yang hyperactivity syndrome after 4 weeks of treatment;Change in diastolic blood pressure from baseline after 4 weeks of treatment; | — |
Countries
China
Contacts
Public ContactLong Linzi
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Outcome results
None listed